Loading
The freshest signals in cancer: new papers, trial results, approvals and law, updated with every build.
Ranked newest first, with approvals, withdrawals and phase 3 results counting as two weeks fresher than their date, other results, law and papers in the leading journals one week fresher, and preprints one week older; every kind keeps its most recent items so no filter is empty while its source has data. Within a day the weightier items come first. Pick types to combine them; For you narrows to the cancer chosen in For me (a choice that stays in this browser); the first filter reads the full 500-item feed.
200 items on this page.
1100 changelog entries, 5 corrections.
openFDA has a label for "Aspirin".
EMA register: Casgevy (exagamglogene autotemcel) Authorised, 2024-02-09.
EMA register: Cystagon (mercaptamine bitartrate) Authorised, 1997-06-23.
EMA register: Entyvio (vedolizumab) Authorised, 2014-05-22.
EMA register: Libmeldy (autologous CD34+ cells encoding ARSA gene) Authorised, 2020-12-17.
EMA register: Lumeblue (previously Methylthioninium chloride Cosmo) (methylthioninium chloride) Authorised, 2020-08-19.
EMA register: Lynkuet (elinzanetant) Authorised, 2025-11-17.
EMA register: NeoRecormon (epoetin beta) Authorised, 1997-07-16.
EMA register: Nezglyal (leriglitazone) Authorised, 2026-09-21.
EMA register: Procysbi (mercaptamine) Authorised, 2013-09-05.
EMA register: SomaKit TOC (edotreotide) Authorised, 2016-12-08.
EMA register: Strimvelis (autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) Authorised, 2016-05-26.
EMA register: Waskyra (etuvetidigene autotemcel) Authorised, 2026-01-09.
EMA register: Xromi (hydroxycarbamide) Authorised, 2019-07-01.
EMA register: Yartemlea (Narsoplimab) Opinion.
EMA register: Zefylti (filgrastim) Application withdrawn.
EMA register: Rasonque (Daraxonrasib) Opinion.
ClinicalTrials.gov overall status is COMPLETED; recorded recruiting.
ClinicalTrials.gov overall status is WITHDRAWN; recorded recruiting.
ClinicalTrials.gov overall status is TERMINATED; recorded active.
1100 changelog entries, 5 corrections.
Published on 28 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.
1068 changelog entries, 3 corrections.
Posted on Preprints.org on 27 October 2026; not peer reviewed; matched Ultrasound, Patient-derived organoids and ATR.
Posted on Research Square on 27 October 2026; not peer reviewed; matched MET and SET.
Posted on Research Square on 27 October 2026; not peer reviewed; matched Tislelizumab, Nintedanib and SBRT / SABR.
Posted on Research Square on 27 October 2026; not peer reviewed; matched Prednisone and mTOR.
Posted on Preprints.org on 27 October 2026; not peer reviewed; matched Azacitidine, Decitabine + cedazuridine and Tretinoin.
Posted on bioRxiv on 27 October 2026; not peer reviewed; matched Azacitidine, Decitabine + cedazuridine and Proteomics & phosphoproteomics.
Posted on Research Square on 27 October 2026; not peer reviewed; matched ALK, Arsenic trioxide and MYCN.
Posted on bioRxiv on 27 October 2026; not peer reviewed; matched Vincristine, ID3 and CASZ1.
Posted on Research Square on 27 October 2026; not peer reviewed; matched Azacitidine, Decitabine + cedazuridine and MET.
Posted on Research Square on 27 October 2026; not peer reviewed; matched MMP2.
Posted on bioRxiv on 27 October 2026; not peer reviewed; matched RNA sequencing & expression profiling, Targeted alpha therapy and Etoposide.
Posted on bioRxiv on 27 October 2026; not peer reviewed; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and MRD / molecular residual disease testing.
Posted on bioRxiv on 27 October 2026; not peer reviewed; matched COX-2 and STAT1.
Posted on bioRxiv on 27 October 2026; not peer reviewed; matched Pertuzumab and Proteomics & phosphoproteomics.
Posted on bioRxiv on 27 October 2026; not peer reviewed; matched STAT3.
Posted on Research Square on 27 October 2026; not peer reviewed; matched NT5C2, Stereotactic radiosurgery and Gamma Knife.
Posted on Research Square on 27 October 2026; not peer reviewed; matched Doxorubicin.
Posted on Research Square on 27 October 2026; not peer reviewed; matched Azacitidine, Decitabine + cedazuridine and Cxbladder.
Posted on Research Square on 27 October 2026; not peer reviewed; matched BRAF, NRAS and NF1.
Posted on bioRxiv on 27 October 2026; not peer reviewed; matched Immune checkpoint inhibitors.
Posted on bioRxiv on 27 October 2026; not peer reviewed; matched YES1.
Posted on medRxiv on 27 October 2026; not peer reviewed; matched CCDC6.
Posted on Research Square on 27 October 2026; not peer reviewed; matched Methotrexate.
Posted on Preprints.org on 27 October 2026; not peer reviewed; matched Mammography & tomosynthesis and CCDC6.
Posted on Research Square on 27 October 2026; not peer reviewed; matched HIF-1α and RANBP2.
Posted on Research Square on 27 October 2026; not peer reviewed; matched PET/CT, PSMA PET and Radioligand therapy.
Posted on Preprints.org on 27 October 2026; not peer reviewed; matched CCDC6.
Posted on Research Square on 27 October 2026; not peer reviewed; matched Nintedanib.
Posted on Research Square on 27 October 2026; not peer reviewed; matched Monoclonal antibodies and PD-1.
Posted on Research Square on 27 October 2026; not peer reviewed; matched CAR-T cell therapy, HER2 and B7-H3.
Posted on medRxiv on 27 October 2026; not peer reviewed; matched HPV & HBV vaccination.
Posted on bioRxiv on 27 October 2026; not peer reviewed; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and State.
Posted on Research Square on 27 October 2026; not peer reviewed; matched Ifosfamide.
Posted on Research Square on 27 October 2026; not peer reviewed; matched Cisplatin and Platinum agents.
Posted on Research Square on 27 October 2026; not peer reviewed; matched ELL.
Posted on bioRxiv on 27 October 2026; not peer reviewed; matched Single-cell & spatial profiling and Spatial transcriptomics.
Posted on Research Square on 27 October 2026; not peer reviewed; matched RNA sequencing & expression profiling and Single-cell & spatial profiling.
Posted on bioRxiv on 27 October 2026; not peer reviewed; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and KRAS.
Posted on Research Square on 27 October 2026; not peer reviewed; matched Cobimetinib, MRI and Capmatinib.
Posted on bioRxiv on 27 October 2026; not peer reviewed; matched CAR-T cell therapy, CD19 and CD58.
On October 26, 2026, the Food and Drug Administration (FDA) approved talazoparib (Talzenna, Pfizer Inc.) in combination with enzalutamide for the treatment of adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test.
Published on 26 October 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics.
Published on 26 October 2026 after first appearing as a preprint; matched MET, State and CIITA.
Published on 26 October 2026 after first appearing as a preprint; matched Whole-exome & whole-genome sequencing, RNA sequencing & expression profiling and Single-cell & spatial profiling.
Published on 26 October 2026 after first appearing as a preprint; matched PROTACs & molecular glues, Proteasome and Cereblon.
Published on 26 October 2026 after first appearing as a preprint; matched ATR, ATM and CIP2A.
Published in Med Lett Drugs Ther on 26 October 2026; matched the OnCo record for Iberdomide.
Published on 26 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling, Spatial transcriptomics and BTG2.
Published on 26 October 2026 after first appearing as a preprint; matched HPV & HBV vaccination.
1065 changelog entries, 3 corrections.
Published on 26 October 2026 after first appearing as a preprint; matched Atlas and ARAF.
Published on 26 October 2026 after first appearing as a preprint; matched State.
Published on 26 October 2026 after first appearing as a preprint; matched State.
Published on 26 October 2026 after first appearing as a preprint; matched CRISPR functional genomics, ATR and BRCA1 / BRCA2.
Published on 26 October 2026 after first appearing as a preprint; matched BCL11A.
Published on 26 October 2026 after first appearing as a preprint; matched Whole-exome & whole-genome sequencing.
Published on 26 October 2026 after first appearing as a preprint; matched Decitabine, SLC6A2 and HSPA5.
Published in Ann Oncol on 25 October 2026; found by the roadmap watch for AZUR-1.
Published on 25 October 2026 after first appearing as a preprint; matched REL, RELA and CD40.
Published on 25 October 2026 after first appearing as a preprint; matched MEF2C, MAML2 and CRTC1.
Published in Ann Oncol on 24 October 2026; found by the roadmap watch for ACTICCA-1.
Published in Ann Oncol on 24 October 2026; found by the roadmap watch for FOURLIGHT-1.
Published in Ann Oncol on 24 October 2026; found by the roadmap watch for CheckMate 8HW.
Published in Ann Oncol on 24 October 2026; found by the roadmap watch for postMONARCH.
Published on 24 October 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics, Epigenetic drugs and EZH2.
Published on 24 October 2026 after first appearing as a preprint; matched KMT2A (MLL) rearrangement, Rituximab and Doxorubicin.
Published on 24 October 2026 after first appearing as a preprint; matched Histopathology & immunohistochemistry, Antibody-drug conjugate and Immune checkpoint inhibitors.
Published on 24 October 2026 after first appearing as a preprint; matched CLTC and CD4.
Published on 24 October 2026 after first appearing as a preprint; matched IRF8.
Published on 24 October 2026 after first appearing as a preprint; matched KLK3.
Published on 24 October 2026 after first appearing as a preprint; matched CT.
Published on 24 October 2026 after first appearing as a preprint; matched Pertuzumab, Atlas and Ki-67.
Published in Ann Oncol on 23 October 2026; found by the roadmap watch for SANO.
Published in Ann Oncol on 23 October 2026; found by the roadmap watch for CAPItello-281.
Published in Nat Med on 23 October 2026; found by the roadmap watch for AMPLIFY-7P.
Published in Ann Oncol on 23 October 2026; found by the roadmap watch for NATALEE.
Published on 23 October 2026 after first appearing as a preprint; matched Mesenchymal stromal cells for tissue damage.
Published on 23 October 2026 after first appearing as a preprint; matched State and ASCL1.
Published on 23 October 2026 after first appearing as a preprint; matched Synthetic lethality approaches, APC and MXI1.
Published on 23 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.
Published on 23 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling.
Published on 23 October 2026 after first appearing as a preprint; matched PRC1.
Published on 23 October 2026 after first appearing as a preprint; matched PARP.
Published on 23 October 2026 after first appearing as a preprint; matched CRAF, Trametinib and ARAF.
Published on 23 October 2026 after first appearing as a preprint; matched DNA methylation profiling.
Published on 23 October 2026 after first appearing as a preprint; matched Venetoclax and MECOM.
Published on 23 October 2026 after first appearing as a preprint; matched Azacitidine and Decitabine + cedazuridine.
Published on 23 October 2026 after first appearing as a preprint; matched MYC.
Published on 23 October 2026 after first appearing as a preprint; matched DNA methylation profiling and TET2.
Published on 22 October 2026 after first appearing as a preprint; matched Scalp cooling.
Published on 22 October 2026 after first appearing as a preprint; matched Transarterial chemoembolisation, Oligonucleotide therapeutics and HIF-1α.
Published on 22 October 2026 after first appearing as a preprint; matched State and Metformin as an anti-ageing drug after cancer.
Published on 22 October 2026 after first appearing as a preprint; matched Interferon alpha receptor and IFNGR1.
1043 changelog entries, 1 upcoming date, 1 correction.
Published on 22 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling, Proteomics & phosphoproteomics and Nicheformer.
Published on 22 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and Spatial transcriptomics.
Published on 22 October 2026 after first appearing as a preprint; matched NR4A3.
Published on 22 October 2026 after first appearing as a preprint; matched Atlas.
Published on 22 October 2026 after first appearing as a preprint; matched LATS1.
Published on 22 October 2026 after first appearing as a preprint; matched DNA methylation profiling and State.
Published in Lancet on 21 October 2026; found by the roadmap watch for NICHE-2.
Published on 21 October 2026 after first appearing as a preprint; matched Cxbladder, PSMC4 and RPS6.
Published on 21 October 2026 after first appearing as a preprint; matched EDNRA.
Published on 21 October 2026 after first appearing as a preprint; matched State, ASCL1 and OLIG2.
Published on 21 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, AKT and BRCA1 / BRCA2.
Published on 21 October 2026 after first appearing as a preprint; matched MRI, RNA sequencing & expression profiling and State.
Published on 21 October 2026 after first appearing as a preprint; matched PD-1, SRC family kinases and CD28.
Published on 21 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling and Single-cell & spatial profiling.
Published on 21 October 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics and HLA-A.
Published on 21 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling, State and ARID1A.
Published on 21 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling, PARP inhibitors and Olaparib.
Published on 21 October 2026 after first appearing as a preprint; matched HRD & BRCA testing and BRCA1 / BRCA2.
Published on 21 October 2026 after first appearing as a preprint; matched HER2 and CALR.
Published on 21 October 2026 after first appearing as a preprint; matched EGFR, AKT and BCL-2.
1030 changelog entries, 1 upcoming date, 1 correction.
Published on 21 October 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling and SET.
Published on 21 October 2026 after first appearing as a preprint; matched Single-cell & spatial profiling, Atlas and mTOR.
Published on 20 October 2026 after first appearing as a preprint; matched Immune checkpoint inhibitors, PD-1 and Nivolumab.
Published on 20 October 2026 after first appearing as a preprint; matched Mathematical models of cancer.
Published on 20 October 2026 after first appearing as a preprint; matched Multiparametric prostate MRI and MRI.
Published on 20 October 2026 after first appearing as a preprint; matched LMNA.
Published in Subst Use Addctn J on 20 October 2026; found by the roadmap watch for OPT-IN.
Published on 20 October 2026 after first appearing as a preprint; matched PAX7.
Published on 20 October 2026 after first appearing as a preprint; matched NR5A2 and CD4.
On October 19, 2026, the Food and Drug Administration granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with Stage II/III locally advanced rectal cancer (LARC) that is microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-authorized test for solid tumors.
On October 16, 2026, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥13 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
Published in Ann Oncol on 16 October 2026; matched the OnCo record for Camrelizumab.
Published in Blood on 16 October 2026; matched the OnCo record for CBL.
Published in JAMA Oncol on 15 October 2026; found by the roadmap watch for ClarIDHy.
Published in Cancer Discov on 15 October 2026; matched the OnCo record for Cabergoline.
Published in Science on 15 October 2026; matched the OnCo record for Teniposide.
Published in Ann Oncol on 15 October 2026; matched the OnCo record for Oesophageal cancer.
On October 14, 2026, the Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.) with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Published in Nature on 14 October 2026; matched the OnCo record for CDKN2B.
Published in J Clin Oncol on 14 October 2026; matched the OnCo record for High-dose-rate brachytherapy.
Published in Nature on 14 October 2026; matched the OnCo record for ELP1.
Published in Ann Oncol on 14 October 2026; matched the OnCo record for WEE1.
Published in Nat Med on 14 October 2026; matched the OnCo record for NeoVax.
Published in J Clin Oncol on 14 October 2026; matched the OnCo record for Selpercatinib.
Published in Nat Med on 14 October 2026; matched the OnCo record for Talazoparib.
Published in J Clin Oncol on 14 October 2026; matched the OnCo record for NRG1.
On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer.
On October 7, 2026, the Food and Drug Administration approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
On October 2, 2026, the Food and Drug Administration approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.
On September 24, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.
On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Accelerated approval (Etcamah) The confirmatory requirement was still open 0.0 years later, when the FDA's table was read.
On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
Withdrawn: the indication came off the label 2.3 years after its accelerated approval.
NDA 220910 approved as Rasonque: adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Withdrawn: the indication came off the label 6.4 years after its accelerated approval.
Withdrawn: the indication came off the label 6.0 years after its accelerated approval.
Withdrawn: the indication came off the label 5.9 years after its accelerated approval.
Programme deprioritised after regulatory feedback on Duravelo-2 design.
For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State: Arm A: Lazertinib With Amivantamab SC-CF 206 micrograms per milliliters (mcg/ml) versus Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion 144 micrograms per milliliters (mcg/ml).
Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator: BRCA Subgroup: Placebo With Abiraterone Acetate Plus Prednisone 25.99 months, hazard ratio 0.515.
Overall Survival (OS): Nofazinlimab + Lenvatinib 21.6 months versus Placebo + Lenvatinib 18.5 months.
Major Pathological Response (MPR) - IASLC Method: Osimertinib + Chemo 25.6 % versus Osimertinib 24.8 % versus Placebo + Chemo 1.7 %.
Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale: Nivo + Rela FDC SC 4.141 ug/ml versus Nivo + Rela FDC IV 3.901 ug/ml.
Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original Scale: Nivolumab SC 77.373 μg/ml versus Nivolumab IV 36.875 μg/ml versus Nivo SC Process C 75.504 μg/ml versus Nivo SC Process D 75.596 μg/ml.
Progression Free Survival (PFS): Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 8.4 months versus Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 4.4 months, hazard ratio 0.43.
Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Interim Analysis): Asciminib 16 participants versus Nilotinib 34 participants, hazard ratio 0.45.
Median disease-free survival 9.30 against 5.55 months (hazard ratio 0.79, p=0.107): primary endpoint not met.
Red Blood Cell-transfusion Independence (RBC-TI) ≥ 12 Weeks (RBC-TI 12): Treatment 23.08 % versus Control 13.33 %.
PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).
Overall survival 17.7 vs 18.0 months (HR 0.92, p 0.32) overall and 20.4 vs 20.4 months (HR 1.05) in PIK3CA/AKT1/PTEN-altered tumours; PFS 5.6 vs 5.1 months (HR 0.72).
Co-primary endpoints including OS met (July 2026); numbers pending.
Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.
Stopped early; primary endpoint not met.
Marketing authorisation withdrawn in the European Union in 2026: Authorised May 2021; marketing authorisation withdrawn at Secura Bio's request 16 Feb 2026 (commercial reasons).
Marketing authorisation withdrawn in the European Union in 2025: Mimpara: authorised 22 Oct 2004; marketing authorisation withdrawn 18 Dec 2025.
Marketing authorisation withdrawn in the European Union in 2025: MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing).
A 2025 EU regulation that gives patients electronic access to their health records across the Union and creates national bodies that can grant researchers, regulators and companies permission to use anonymised or pseudonymised health data, phased in over the rest of the decade.
Everything above is read at build time from snapshots and records already in the repository; nothing is fetched when the page is viewed. Where each kind comes from and how often its source refreshes, from the workflow schedules in .github/workflows:
FDA Oncology Center of Excellence approval notifications (public/fda/recent.json), dated approvals recorded on product pages, and European Commission authorisations from the regional approvals table with an EPAR or regulator link.
Refresh: FDA feed Wednesdays 06:07 UTC (refresh-fda.yml); EU rows checked against the EMA register Wednesdays 06:37 UTC (refresh-regional.yml); product pages by hand.
Dated withdrawals recorded on product pages and withdrawn EU authorisations in the regional approvals table, each with a source link.
Refresh: Same schedule as approvals.
Trials in the corpus with a reported year and structured outcomes, linked to the primary paper, sponsor release or registry entry the outcome cites.
Refresh: Curated by hand; ClinicalTrials.gov status refreshed Mondays 06:17 UTC (refresh-trials.yml).
The newest Europe PMC matches for every product, target, cancer and technology (public/papers), journal versions of tracked preprints, and papers the roadmap watch found for landmark trials. One entry per DOI, however many records it matched.
Refresh: Literature snapshot Tuesdays 05:41 UTC (refresh-papers.yml); roadmap watch Thursdays 05:29 UTC (roadmap-watch.yml).
bioRxiv, medRxiv, Research Square and other preprints of the last 90 days that match a target, product or technology query (public/preprints). Not peer reviewed.
Refresh: Wednesdays 06:17 UTC (refresh-preprints.yml).
Statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made, each linked to its primary text.
Refresh: Curated by hand; new instruments are added when they are enacted.
Changes the nightly bot proposes for the corpus from the FDA feed, the EMA register and registry status changes (public/proposals/latest.json). Proposals, not facts: each waits for a human to apply it.
Refresh: Daily 03:23 UTC (propose.yml).
OnCo's own weekly issue: what changed, regulatory events, upcoming readouts and what the journals published.
Refresh: Mondays 07:31 UTC (newsletter.yml); the archive is rebuilt with every deploy.
Dates are shown at the precision the source gives: a year-only law or authorisation is grouped under its year, never given a day. Papers are matched to records by their literature queries, so a code or a common word can pull in an unrelated paper; the record chips tell you what matched. Not medical advice.